Research Progress on Ferroptosis as a Therapeutic Strategy in Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Research Progress on Ferroptosis as a Therapeutic Strategy in Renal Cell Carcinoma

Published:2022-12-16 Issue: Volume: Page:
ISSN:2617-7773
Container-title:annals of urologic oncology
language:en
Short-container-title:ann urol oncol

Author:

Minna Liu¹,Bai Min²,Cui Na,Ding Yi²,Zhang Peng

Affiliation:

1. Department of Nephrology, The 940th Hospital Joint Logistics Support Forces of PLA, Xi'an, Shaanxi, P.R. China.

2. Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China.

Abstract

Renal cell carcinoma (RCC) is a common type of kidney cancer in adults and constitutes approximately 90% of all renal malignancies. Although advancements have been made in the treatment of RCC, the 5 -year survival rate is still low, and new treatment modalities are still required. Ferroptosis is an iron-dependent programmed cell death caused by the accumulation of lipid peroxide products. Recent studies revealed the involvement of ferroptosis metabolism, lipid peroxidation, and System XC-GSH-GPX4 shafts as major mechanisms closely related to RCC progression. Nanoparticles in combination with small molecular ferroptosis induction agents have the advantages of solubility, targeted enhancement, low systemic toxicity, controllable drug control, and synergy advantage in emerging combination therapies. In the future, it is possible to be used in nano treatment. The relationship between ferroptosis-related mechanisms and RCC progression and its role in the treatment could provide novel treatment strategies for patients with advance-stage RCC.

Publisher

Asian Medical Press Limited

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference51 articles.

1. Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, Kassouf W, Mitchell T, Montironi R, O'Brien T et al: Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol 2022, 82(5): 529-542.

2. Capitanio U, Montorsi F: Renal cancer. Lancet 2016, 387(10021): 894-906.

3. Jonasch E, Gao J, Rathmell WK: Renal cell carcinoma. BMJ 2014, 349: g4797.

4. Bex A, Gore M, Mulders P, Sternberg CN: Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care. BJU Int 2012, 110(9): 1289-1300.

5. Atkins MB, Tannir NM: Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev 2018, 70: 127-137.